The interactions between protein and ligand are crucial to practically every biological function in the body, and investigations of these interactions are critical from the perspective of logical medication development. In this work, several biophysical methods like UV–Visible spectroscopy, fluorescence spectroscopy, and in-silico studies have been explored to examine the interaction between aceclofenac and haemoglobin. Spectrofluorimetric data confirmed the static nature of the protein quenching mechanism caused by the medication. ΔG for the formation of the complex via the interaction was found to be − 12.65 kJ/mol. Molecular docking showed a strong interaction between aceclofenac and hemoglobin with a binding energy of − 31.79 kJ/mol. Further, molecular dynamics simulations using Gromacs were run to investigate the stability of the protein with and without aceclofenac, and the ΔG for the formation of the complex (hemoglobin-aceclofenac) is − 105.09 kJ/mol with an error of 13.51 kJ/mol. Spectroscopic and in-silico calculations indicate the feasible binding of the aceclofenac with hemoglobin. Further, the interaction of haemoglobin with aceclofenac was studied by cyclic voltammetry. Graphical Abstract
In our continuing search for new anticancer and/or antimicrobial compounds from natural products, we screened for these activities in bark and leaf extracts of sandalwood plants collected from the Fiji Islands and found Santalum yasi to be the most active. Resulting chemical workup enabled the isolation and structural characterization of a new acetylenic acid, methyl (E)-octadec-6-en-8-ynoate (1), and an atropisomeric stilbene glycoside (4) (Yasibeneoside) together with six known compounds: 11,13-octadecadien-9-ynoic acid (2), methyl octadeca-9,11-diynoate (3), gaylussacin (5) chrysin-7-beta-monoglucoside (6), neoschaftoside (7), and chrysin-6-C-glucoside-8-C-arabinoside (8). Compound 1 (18:2 (6t, 8a) is an example of a Δ6, Δ8 acetylenic system containing the trans double bond at C-6 and the triple bond at C-8, which is reported here for the first time. All molecular structure elucidations and dereplications were performed using spectroscopic techniques, including 2D NMR and HRMS-MS/MS spectrometry. Methyl (E)-octadec-6-en-8-ynoate showed moderate activity activity with an IC50 of 91.2 ug/mL against the human breast adenocarcinoma cell line MCF-7.